Challenges in the development and reimbursement of personalized medicine-payer and manufacturer perspectives and implications for health economics and outcomes research: A report of the ISPOR personalized medicine special interest group

Value in Health

Volumn 15, Issue 8, 2012, Pages 1162-1171

  Faulkner, Eric ^a,b,c,d   Annemans, Lieven ^e   Garrison, Lou ^f   Helfand, Mark ^g   Holtorf, Anke Peggy ^h   Hornberger, John ^i,j   Hughes, Dyfrig ^k   Li, Tracy ^l   Malone, Daniel ^m   Payne, Katherine ⁿ   Siebert, Uwe ^o,p,q   Towse, Adrian ^r   Veenstra, David ^f   Watkins, John ^s  

^a IQVIA   (United States)

^b RTI HEALTH SOLUTIONS   (United States)

^c National Association of Managed Care Physicians   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

^e GHENT UNIVERSITY   (Belgium)

^f UNIVERSITY OF WASHINGTON   (United States)

^g OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^h Health Outcomes Strategies   (Switzerland)

ⁱ Cedar Associates   (United States)

^j STANFORD UNIVERSITY   (United States)

^k BANGOR UNIVERSITY   (United Kingdom)

^l DAIICHI SANKYO INC   (United States)

^m UNIVERSITY OF ARIZONA   (United States)

ⁿ UNIVERSITY OF MANCHESTER   (United Kingdom)

^o UNIVERSITY FOR HEALTH SCIENCES   (Austria)

^p HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^q Oncotyrol Center for Personalized Cancer Medicine   (Austria)

^r Office of Health Economics   (United Kingdom)

^s Premera Blue Cross   (United States)

more..

Author keywords

diagnostics; health economics and outcomes research; health technology assessment; personalized medicine; reimbursement

Indexed keywords

ARTICLE; CLINICAL PRACTICE; DRUG MANUFACTURE; HEALTH ECONOMICS; HUMAN; MEDICAL SOCIETY; OUTCOME ASSESSMENT; PATIENT DECISION MAKING; PERSONALIZED MEDICINE; PRIORITY JOURNAL; REIMBURSEMENT;

BIOMEDICAL RESEARCH; DRUG INDUSTRY; ECONOMICS, PHARMACEUTICAL; HEALTH SERVICES ACCESSIBILITY; HUMANS; INDIVIDUALIZED MEDICINE; INSURANCE, HEALTH, REIMBURSEMENT; OUTCOME ASSESSMENT (HEALTH CARE); PHARMACOGENETICS; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 84871217315     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2012.05.006     Document Type: Article

References (83)

1. President's Council of Advisors on Science and Technology Priorities for Personalized Medicine 2008 President's Council of Advisors on Science and Technology Washington, DC
2. H. Willard, and G. Ginsburg Essentials of Genomic and Personalized Medicine 2010 Academic Press
3. A. Huriez Personalized medicine in Europe: challenges and opportunities European Personalized Medicine Association, 4th Luxinnovation Forum May 2011 http://www.business-meets-research.lu/fileadmin/user-upload/presentations-2011/ BioHealth-EPEMED.pdf [Accessed July 4, 2011]
4. R.M. Califf Defining the balance of risk and benefit in the era of genomics and proteomics Health Aff 23 2004 77 87 (Pubitemid 39107150)
5. E. Faulkner Addressing the realities of health care in the 21st century: a time for collaborative solutions J Manag Care Med 2 2005 11 12
6. A.C. Gelijns, L. Brown, and C. Magnell Evidence, politics, and technological change Health Aff 24 2005 29 40 (Pubitemid 40173933)
7. Institute of Medicine Policy Issues in the Development of Personalized Medicine in Oncology Summary of a National Cancer Policy Forum workshop on Policy Issues in the Development of Personalized Medicine in Oncology, June 2009 2010 Institute of Medicine Washington, DC
8. Secretary's Advisory Group on Genetics, Health and Society Realizing the Promise of Pharmacogenomics: Opportunities and Challenges 2007 Department of Health and Human Services Bethesda, MD
9. The Lewin Group The Value of Diagnostics: Innovation, Adoption and Diffusion Into Health Care Prepared for AdvaMed, Washington, DC 2005 The Lewin Group Falls Church, VA
10. Science and Technology Committee, House of Lords Genomic Medicine, Enquiry Report 2009 House of Lords London, England
11. J.L. Fackler, and A.L. McGuire Paving the way to personalized genomic medicine: steps to successful implementation Curr Pharmacogenomics Person Med 7 2009 125
12. D.A. Henry, S.R. Hill, and A. Harris Medicine prices and value for money: the Australian Pharmaceutical Benefits Scheme JAMA 294 2005 2630 2632 (Pubitemid 41697253)
13. A.R. Mason, and M.F. Drummond Public funding of new cancer medicines: is NICE getting nastier? Eur J Cancer 45 2009 1188 1192
14. J. Lexchin, and B. Mintzes Medicine reimbursement recommendations in Canada, Australia, and Scotland Am J Manag Care 14 2008 581 588
15. L. Chim, P.J. Kelly, G. Salkeld, and M.R. Stockler Are cancer medicines less likely to be recommended for listing by the Pharmaceutical Benefits Advisory Committee in Australia? Pharmacoeconomics 28 2010 463 475
16. F.M. Clement, A. Harris, and J.J. Li Using effectiveness and cost-effectiveness to make medicine coverage decisions: a comparison of Britain, Australia, and Canada JAMA 302 2009 1437 1443
17. P.A. Deverka, and H.L. McLeod Harnessing economic drivers for successful clinical implementation of pharmacogenetic testing Clin Pharmacol Ther 84 2008 191 193
18. L.P. Garrison Jr, R.J. Carlson, and J.J. Carlson A review of public policy issues in promoting the development and commercialization of pharmacogenomic applications: challenges and implications Med Metab Rev 40 2008 377 401 (Pubitemid 352002781)
19. K.A. Phillips, D.L. Veenstra, and S.D. Ramsey Genetic testing and pharmacogenomics: issues for determining the impact to healthcare delivery and costs Am J Manag Care 10 7, Pt 1 2004 425 432 (Pubitemid 38970239)
20. Y. Chen, E. Bord, and T. Tompkins Asymptomatic reactivation of JC virus in patients treated with natalizumab N Engl J Med 361 2009 1067 1074
21. I.L. Ferrusi, D.A. Marshall, and N.A. Kulin Looking back at 10 years of trastuzumab therapy: what is the role of HER2 testing? A systematic review of health economic analyses Per Med 6 2009 193 215
22. A. Hochhaus, S.G. O'Brien, and F. Guilhot Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia Leukemia 23 2009 1054 1061
23. K. Dalziel, A. Round, and K. Stein Effectiveness and cost-effectiveness of imatinib for first-line treatment of chronic myeloid leukaemia in chronic phase: a systematic review and economic analysis Health Technol Assess 8 2004 1 120 iii
24. A.C. Wolff, M.E. Hammond, and J.N. Schwartz American Society of Clinical Oncology, College of American Pathologists American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer J Clin Oncol 25 2007 118 145 (Pubitemid 350003059)
25. National Institute for Health and Clinical Excellence Gefitinib for the First-Line Treatment of Locally Advanced or Metastatic Non-Small-Cell Lung Cancer Final Appraisal Determination 2010 NICE London
26. Pharmacy Benefits Advisory Committee November 2009 PBAC outcomes-positive recommendations http://www.pbs.gov.au/info/industry/listing/elements/pbac- meetings/pbac-outcomes/2009-11/a-positive-recommend [Accessed February 10, 2011]
27. Cigna Gefitinib (Iressa): Cigna medical coverage policy number 4002 http://www.cigna.com/customer-care/healthcare-professional/coverage-positions/ pharmacy/ph-4002-coveragepositioncriteria-iressa.pdf [Accessed February 10, 2011]
28. W.B. Wong, J.J. Carlson, R. Thariani, and D.L. Veenstra Cost effectiveness of pharmacogenomics: a critical and systematic review Pharmacoeconomics 28 2010 1001 1013
29. T.I. Verhoef, W.K. Redekop, and J. Darba A systematic review of cost-effectiveness analyses of pharmacogenetic-guided dosing in treatment with coumarin derivatives Pharmacogenomics 11 2010 989 1002
30. E. Faulkner, B. Quinn, K. Trakas, and L. Garrison What can we learn from successes and failures in personalized medicine? Implications for evolving health outcomes and economics research practices Presented at the International Society for Pharmacoeconomics and Outcomes Research 16th Annual International Meeting Baltimore, MD May 2011
31. D. Paci, and D. Ibarreta Economic and cost-effectiveness considerations for pharmacogenetics tests: an integral part of translational research and innovation uptake in personalized medicine Curr Pharmacogenomics Person Med 7 2009 284 296
32. Centers for Medicare & Medicaid Services National Coverage Determination (NCD) for pharmacogenomic testing for warfarin response (90.1) http://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId= 333&ncdver=1&bc=BAAAgAAAAAAA& 2010 [Accessed February 11, 2011]
33. Cigna Pharmacogenetic testing: Cigna medical coverage policy number 0500 http://www.cigna.com/customer-care/healthcare-professional/coverage-positions/ medical/mm-0500-coveragepositioncriteria-pharmacogenetic-testing.pdf [Accessed February 11, 2011]
34. Scottish Medicines Consortium Resubmission for gefitinib 250mg film-coated tablets (Iressa) Appraisal No. 615/10 http://www.scottishmedicines. org.uk/files/advice/gefitinib-Iressa-RESUBMISSION-FINAL-November-2010-for- website.pdf November 5, 2010 [Accessed February 2, 2011]
35. T. Brown, A. Boland, and A. Bagust Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer Health Technol Assess 14 Suppl. 2 2010 71 79
36. US Food and Drug Administration Draft guidance for industry and Food and Drug Administration staff: in vitro companion diagnostic devices http://www.fda.gov/medicaldevices/deviceregulationandguidance/guidancedocuments/ ucm262292.htm July 14, 2011 [Accessed July 20, 2011]
37. E. Faulkner Clinical utility or impossibility? Addressing the molecular diagnostics health technology assessment and reimbursement conundrum J Manag Care Med 12 2009 42 55
38. J.R. Trosman, S.L. Van Bebber, and K.A. Phillips Health technology assessment and private payers' coverage of personalized medicine Am J Manag Care 17 Suppl. 5 2011 SP53 SP60
39. F.W. Frueh Real-world clinical effectiveness, regulatory transparency and payer coverage: three ingredients for translating pharmacogenomics into clinical practice Pharmacogenomics 11 2010 657 660
40. B. Quinn Payers and the assessment of clinical utility for companion diagnostics Clin Pharmacol Ther 88 2010 751 754
41. J.A. Vernon, S.J. Johnson, W.K. Hughen, and A. Trujillo Economic and developmental considerations for pharmacogenomic technology Pharmacoeconomics 24 2006 335 343
42. A. Finckh, N. Bansback, and C.A. Marra Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic medicines, or biologic agents: a cost-effectiveness analysis Ann Intern Med 151 2009 612 621
43. P.M. Danzon, and M.F. Furukawa Prices and availability of biopharmaceuticals: an international comparison Health Aff (Millwood) 25 2006 1353 1362 (Pubitemid 44497636)
44. P.M. Danzon, and E. Taylor Medicine pricing and value in oncology Oncologist 15 Suppl. 1 2010 24 31
45. Center for the Study of Drug Development, Tufts University Tufts CSDD Impact Report 2010 Tufts CSDD Boston, MA
46. A. Thomas, A. Phillips, R. Donnelly, and C.T. Piech Comparative effectiveness, personalized medicine and innovation: the path forward Pharmacoeconomics 28 2010 923 930
47. K.A. Schulman, and S.R. Tunis A policy approach to the development of molecular diagnostic tests Nat Biotechnol 28 2010 1157 1159
48. L.P. Garrison, and M.J. Austin The economics of personalized medicine: a model of incentives for value creation and capture Med Inform J 41 2007 501 509 (Pubitemid 47041921)
49. E. Faulkner, A. Towse, D. Ossa, and U. Siebert Are diagnostics and personalized medicine in flux? Implications of global policy changes for health economics and outcomes research Presented at the International Society for Pharmacoeconomics and Outcomes Research 13th Annual European Congress Prague, Czech Republic October 2010
50. R. Conti, D. Veenstra, and K. Armstrong Personalized medicine and genomics: challenges and opportunities in assessing effectiveness, cost-effectiveness, and future research priorities Med Decis Making 30 2010 328 340
51. K. Payne Informing resource allocation decision making: economic evaluations of pharmacogenetic tests Med Develop Res 71 2010 445 448
52. S. Hartz, and J. John Contribution of economic evaluation to decision making in early phases of product development: a methodological and empirical review Int J Technol Assess Health Care 24 2008 465 472
53. Agency for Healthcare Research and Quality Evaluating the potential use of modeling and value-of-information analysis for future research prioritization within the evidence-based practice center program http://www. effectivehealthcare.ahrq.gov/ehc/products/220/700/MFRN5-6-10-11.pdf June 2011 [Accessed July 1, 2011]
54. C. Hassan, M. Hunink, and A. Laghi Value-of-information analysis to guide future research in colorectal cancer screening Radiology 253 2009 745 752
55. C. McKenna, C. Zaid, D. Epstein, and K. Claxton Budgetary policies and available actions: a generalisation of decision rules for allocation and research decisions J Health Econ 29 2010 170 181
56. University of York, Center for Health Economics A pilot study of value of information analysis to support research recommendations for NICE http://www.york.ac.uk/media/che/documents/papers/researchpapers/ rp4-Pilot-study-of-value-of-information-analysis.pdf August 2008 [Accessed August 12, 2011]
57. D. Husereau Sentence first, verdict afterwards: using value of information analysis to inform decisions about PGx test adoption and research Curr Pharmacogenomics Person Med 8 2010 167 170
58. Report of the Secretary's Advisory Committee on Genetics, Health, and Society Realizing the potential of pharmacogenomics: opportunities and challenges http://oba.od.nih.gov/oba/SACGHS/reports/SACGHS-PGx-report.pdf May 2008 [Accessed August 12, 2011]
59. Academy of Medical Sciences Global Health Diagnostics: Research, Development and Regulation: Workshop Report 2009 Academy of Medical Sciences London
60. D.F. Hayes, B. Trock, and A.L. Harris Assessing the clinical impact of prognostic factors: when is "statistically significant" clinically useful? Breast Cancer Res Treat 52 1998 305 319 (Pubitemid 29056102)
61. R.M. Simon, S. Paik, and D.F. Hayes Use of archived specimens in evaluation of prognostic and predictive biomarker J Natl Cancer Inst 101 2009 1446 1452
62. M. Drummond, M. Schulpher, and G.W. Torrance Methods for the economic evaluation of health care programmes 2005 Oxford University Press New York
63. M. Gold, J. Siegel, L. Russell, and M. Weinstein Cost-Effectiveness in Health and Medicine 1996 Oxford University Press New York
64. M.F. Drummond, J.S. Schwartz, and B. Jonsson Key principles for the improved conduct of health technology assessments for resource allocation decisions Int J Technol Assess Health Care 24 2008 244 258 (Pubitemid 351950160)
65. U. Siebert When should decision-analytic modeling be used in the economic evaluation of health care? Eur J Health Econ 4 2003 143 150 (Pubitemid 37247966)
66. R.S. Taylor, and C.P. Iglesias Assessing the clinical and cost-effectiveness of medical devices and medicines: are they that different? Value Health 12 2009 404 406
67. K. Redekop Cost-effectiveness analyses of diagnostic strategies: a literature survey using the NHS Economic Evaluation Database Expert Review Pharmacoecon Outcomes Res 6 2006 41 48
68. European Commission Health Research Directorate Personalized medicine: opportunities and challenges for European healthcare In: 13th European Health Forum Gastein http://ec.europa.eu/research/health/pdf/13th-european-health- forum-workshop-report-en.pdf [Accessed May 10, 2011]
69. M.C. Weinstein, B. O'Brien, and J. Hornberger Principles of good research practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices-modeling studies Value Health 6 2003 9 17 (Pubitemid 36228345)
70. P.A. Deverka, J. Vernon, and H.L. McLeod Economic opportunities and challenges for pharmacogenomics Annu Rev Pharmacol Toxicol 50 2010 423 437
71. L. Becla, J.E. Lunshof, and D. Gurwitz Health technology assessment in the era of personalized health care Int J Technol Assess Health Care 27 2011 118 126
72. E. Faulkner, L. Anemans, K. Payne, and U. Siebert The devil is in the details: international comparison of technology assessment processes and payer uptake of personalized medicine and implications for the field Presented at the International Society for Pharmacoeconomics and Outcomes Research 12th Annual European Congress Paris, France October 2009
73. National Institute for Health and Clinical Excellence Diagnostics Assessment Programme: Interim Methods Statement 2010 NICE London
74. Medical Services Advisory Committee (MSAC) and the Pharmaceutical Benefits Advisory Committee (PBAC) Draft information requests for assessing a pair of co-dependant technologies http://www.health.gov.au/internet/hta/ publishing.nsf/Content/14B1C87A7C197EE6CA2577A00012C52D/$File/ codependents.pdf 2010 [Accessed August 12, 2011]
75. The Lewin Group C. Goodman Comparative effectiveness research and personalized medicine: from contradiction to synergy http://www.lewin.com/ content/publications/Lewin-CER-PM.pdf 2009 [Accessed May 15, 2011]
76. R.S. Epstein, and J.R. Teagarden Comparative effectiveness research and personalized medicine: catalyzing or colliding? Pharmacoeconomics 28 2010 905 913
77. S.D. Ramsey, D. Veenstra, and S.R. Tunis How comparative effectiveness can advance personalized medicine in cancer treatment Health Aff 30 2011 2259 2268
78. K. Payne Fish and chips all round? Regulation of genetic-based technologies Health Econ 18 2009 1233 1236
79. Medical Services Advisory Committee KRAS mutation testing for cetuximab (Erbitux) Public Summary Document Reference No. 44 http://www.health.gov.au/ internet/msac/publishing.nsf/Content/D07EFEE30875A258CA257885001AD163/ $File/ FINAL%20PSD%2044%20KRAS%20Cetuximab%20erbitux%20endorsed%20MSAC%2023.2.11.pdf December 2010 [Accessed May 12, 2011]
80. Medical Services Advisory Committee Epidermal growth factor receptor gene testing and access to PBS listed gefitinib Public Summary Document Reference No. 41 http://www.health.gov.au/internet/msac/publishing.nsf/Content/ 38AC1E878215F83BCA25784C0006FBB8/$File/ 41%20EGFR%20Gefitinib%20Final%20PSD%20endorsed%20MSAC%2023.2.11.pdf December 2010 [Accessed May 12, 2011]
81. Canadian Agency for Medicines and Technologies in Health Epidermal growth factor receptor mutation analysis in advanced non-small cell lung cancer: review of economic evaluations and framework for economic analyses http://www.cadth.ca/media/pdf/m0018-egfr-economic-framework-htis-3.pdf July 2010 [Accessed May 1, 2011]
82. S.L. Van Bebber, S.-Y. Liang, and K.A. Phillips Valuing personalized medicine: willingness to pay for genetic testing for colorectal cancer risk Future Med 4 2007 341 350 (Pubitemid 47354517)
83. C. Bonnell, A.H. McGuire, M. Synovec Molecular Pathology Workgroup General Session. American Medical Association http://www.ama-assn.org/ama1/pub/ upload/mm/362/request-for-molecular-pathology-code-review-and-feedback.pdf June 2, 2011 [Accessed August 1, 2011]